LY3305677

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyObesityOverweight

Phase 1

A Study of LY3305677 in Healthy Participants

CompletedNCT02972645

Eli Lilly and CompanyHealthy

Start: 2016-12-05End: 2017-07-14Updated: 2017-07-24

A Study of Multiple Doses of LY3305677 in Healthy Participants

CompletedNCT03325387

Eli Lilly and CompanyHealthy

Start: 2017-10-27End: 2018-08-03Updated: 2018-08-16

A Study of LY3305677 in Participants With Type 2 Diabetes

CompletedNCT03928379

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2019-10-27End: 2021-07-08Updated: 2021-07-19

A Study of LY3305677 in Participants With Obesity Or Overweight

CompletedNCT05623839

Eli Lilly and CompanyObesity, Overweight

Start: 2022-11-16End: 2023-06-27Updated: 2023-07-05

Phase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

RecruitingNCT06143956

Eli Lilly and CompanyObesity, Overweight

Start: 2023-11-17End: 2028-02-01Target: 1481Updated: 2026-09-08

Related Papers

Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial

Diabetes Obesity and Metabolism2025-08-20

333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)

Diabetes2022-05-317 citations